Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
140.8 USD | +1.68% | +1.19% | +6.76% |
Financials (USD)
Sales 2024 * | 2.22B | Sales 2025 * | 2.54B | Capitalization | 13.94B |
---|---|---|---|---|---|
Net income 2024 * | 430M | Net income 2025 * | 661M | EV / Sales 2024 * | 5.38 x |
Net cash position 2024 * | 2B | Net cash position 2025 * | 2.79B | EV / Sales 2025 * | 4.38 x |
P/E ratio 2024 * |
33.8
x | P/E ratio 2025 * |
22
x | Employees | 1,448 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.73% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | +1.71% | ||
1 week | -3.29% | ||
Current month | +0.68% | ||
1 month | +2.84% | ||
3 months | +5.09% | ||
6 months | +23.22% | ||
Current year | +5.10% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.65% | 254 M€ | +10.27% | - | |
3.81% | 1 M€ | -2.17% | - | |
1.85% | 8 M€ | +4.88% | ||
1.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 140.7 | +1.58% | 173 738 |
24-05-14 | 138.5 | +1.71% | 637,476 |
24-05-13 | 136.2 | -0.40% | 712,827 |
24-05-10 | 136.7 | -2.12% | 679,327 |
24-05-09 | 139.7 | +0.46% | 479,494 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.10% | 13.94B | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.70% | 21.25B | |
-6.03% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
+289.58% | 7.99B |
- Stock Market
- Equities
- NBIX Stock